Drugs / 20-valent pneumococcal conjugate vaccine (20vPnC)
20-valent pneumococcal conjugate vaccine (20vPnC)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT06182124 Comparator | Dec 2023 → May 2026 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT07660198 Comparator | Jun 2026 → Dec 2027 expected | pneumococcal infection | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07573462 Comparator | May 2026 → Dec 2028 expected | pneumococcal infection | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 20-valent pneumococcal conjugate vaccine (20vPnC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06182124 ↗ |
| Modality | Vaccine | “pneumococcal vaccine” NCT06182124 ↗ |
| Route | Intramuscular | “single shot into the upper arm muscle” NCT06182124 ↗ |